Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Essex Property Trust, Inc. (ESS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Essex Property Trust, Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Essex Property Trust, Inc. trades at $268.84 (market cap $17.47B). The key difference: Essex Property Trust, Inc. is far larger — about 6.1× Dyne Therapeutics Inc. Common Stock's market cap, and Essex Property Trust, Inc. pays a 3.81% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Essex Property Trust, Inc. for 112 Days on average.
| DYN | ESS | |
|---|---|---|
Market Cap | $2.86B | $17.47B |
Volume | 3,341,579 | 425,157 |
Sector | Health | Real Estate |
52-Week High | $26.78 | $298.33 |
52-Week Low | $14.60 | $239.61 |
Typical Hold Time | 0 Days | 112 Days |
Enterprise Value | $2.18B | $24.07B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
ESS trades at $269.37, down 0.38% with neutral technical signals. The company shows strong profitability with 67.9% gross margins and 21.48% net income, though recent earnings were mixed with Q2 2026 missing expectations. Revenue growth has been steady, reaching $1.89B in 2025. Analyst consensus is mixed with 38.3% buy ratings and a $300.77 price target, representing 11.7% upside. Recent news highlights strong Q2 results and legal resolution.
ESS offers solid fundamentals with premium valuation (P/E 42.35) and strong operational efficiency. Key risks include earnings volatility and high debt levels ($6.46B long-term). The stock presents opportunity from raised guidance and institutional interest, but requires monitoring of West Coast real estate market conditions and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →
